<![CDATA[Paxalisib/Gemcitabine Combination Dosed in First Patient With CNS Tumor]]>

Phase 2PaxalisibGemcitabinePositive

AI Analysis

Summary

The first patient has been dosed in a Phase 2 trial evaluating paxalisib combined with gemcitabine for treating recurrent atypical teratoid/rhabdoid tumor in children and young adults.

Clinical Trial Data

Phase

Phase 2

Patients

Importance:5/10

Sentiment:

0.40

Phase 2OncologyCNS tumorPediatricTrial initiation

Related Companies

$TRAX

Read the original article

Published by Cancer Network on September 9, 2026 6:00 PM

Read Original